Compare · NN vs TMO
NN vs TMO
Side-by-side comparison of NextNav Inc. (NN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NN and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $244.79B, about 114.1x NN ($2.15B).
- Over the past year, NN is down 19.8% and TMO is up 21.9% - TMO leads by 41.8 points.
- NN has been more active in the news (11 items in the past 4 weeks vs 7 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 7 for NN).
- Company
- NextNav Inc.
- Thermo Fisher Scientific Inc
- Price
- $11.61-8.51%
- $651.89-1.49%
- Market cap
- $2.15B
- $244.79B
- 1M return
- -24.76%
- +7.55%
- 1Y return
- -19.85%
- +21.93%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 7
- Recent ratings
- 7
- 25
NextNav Inc.
Spartacus Acquisition Corporation intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Duluth, Georgia.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest NN
- NextNav and AiRANACULUS Partner to Advance Long-Range 5G Sensing and Counter-UAS Detection
- Chief Operating Officer Insley Susan Brasse sold $33,702 worth of shares (2,370 units at $14.22) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 163,835 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Gray Timothy sold $162,538 worth of shares (11,099 units at $14.64) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 120,687 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 144 filed by NextNav Inc.
- NextNav Expands Leadership Team with Two Key Hires
- Chief Accounting Officer Shams Sammaad sold $23,075 worth of shares (1,576 units at $14.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 68,938 units (SEC Form 4) (withholding obligation)
- CEO, President and Director Sorond Mariam sold $41,663 worth of shares (2,831 units at $14.72) as part of a pre-agreed trading plan, decreasing direct ownership by 0.24% to 1,168,961 units (SEC Form 4) to satisfy withholding obligation
- Chief Operating Officer Insley Susan Brasse sold $12,981 worth of shares (849 units at $15.29) as part of a pre-agreed trading plan, decreasing direct ownership by 0.51% to 166,205 units (SEC Form 4) (withholding tax)
- Chief Accounting Officer Shams Sammaad sold $6,360 worth of shares (430 units at $14.79) as part of a pre-agreed trading plan, decreasing direct ownership by 0.61% to 70,514 units (SEC Form 4) (for tax liability)
- General Counsel Black James S sold $28,814 worth of shares (1,878 units at $15.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 89,810 units (SEC Form 4) to satisfy tax liability
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)